Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals Revenue

Alnylam Pharmaceuticals had revenue of $500.92M in the quarter ending September 30, 2024, a decrease of -33.26%. This brings the company's revenue in the last twelve months to $2.09B, up 21.54% year-over-year. In the year 2023, Alnylam Pharmaceuticals had annual revenue of $1.83B with 76.23% growth.

• Revenue (ttm): $2.09B
• Revenue Growth: +21.54%
• P/S Ratio: 14.90
• Revenue / Employee: $997,521
• Employees: 2,100
• Market Cap: 31.76B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	1.83B	790.87M	76.23%
Dec 31, 2022	1.04B	193.13M	22.88%
Dec 31, 2021	844.29M	351.43M	71.31%
Dec 31, 2020	492.85M	273.10M	124.28%
Dec 31, 2019	219.75M	144.84M	193.36%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.